Should HCV-Positive Asymptomatic Patients with Mixed Cryoglobulinemia Be Treated with Combined Antiviral Therapy?

  • José Luis Calleja Panero
  • Juan de la Revilla Negro
  • Fernando Pons Renedo


Mixed cryoglobulinemia (MC) is a lymphoproliferative disorder resulting from immunoglobulin complexes that precipitate in serum in the cold. The disease is associated with a variety of vasculitic manifestations. HCV infection is considered one of the antigenic triggers of MC. HCV patients with circulating cryoglobulins and the absence of symptoms should be managed the same as HCV patients without this hematological condition, as the sustained virological response and safety profile are similar in the two groups of patients. Antiviral therapy with pegylated interferon and ribavirin is the first-line option for symptomatic HCV-related MC, with an excellent clinical response of cutaneous and rheumatologic manifestations and a partial effect on renal and neurologic complications, even without viral response. Viral eradication is usually accompanied by a maintained complete clinical and immunological response. Immunomodulatory agents, newly developed biologics therapy, and plasma exchange should be reserved for patients with severe or life-threatening manifestations. They provide temporary relief from the disease so that additional antiviral therapy can then be initiated.


Sustained Virological Response Antiviral Therapy Virological Response Sustained Virological Response Rate Mixed Cryoglobulinemia 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


  1. 1.
    Pascual M, Perrin L, Giostra E, Schifferli JA (1990) Hepatitis C virus in patients with cryoglobulinemia type II. J Infect Dis 162:569–570PubMedCrossRefGoogle Scholar
  2. 2.
    Kayali Z, Buckwold VE, Zimmerman B, Schmidt WN (2002) Hepatitis C, cryoglobulinemia, and cirrhosis: a meta-analysis. Hepatology 36:978–985PubMedGoogle Scholar
  3. 3.
    Ferri C (2008) Mixed cryoglobulinemia. Orphanet J Rare Dis 3:25–42PubMedCrossRefGoogle Scholar
  4. 4.
    Polzien F, Schott P, Mihm S et al (1997) Interferon-α treatment of hepatitis C virus-associated mixed cryoglobulinemia. J Hepatol 27:63–71PubMedCrossRefGoogle Scholar
  5. 5.
    Schott P, Hartmann H, Ramadori G (2001) Hepatitis C virus-associated mixed cryoglobulinemia. Clinical manifestations, histopathological changes, mechanisms of cryoprecipitation and options of treatment. Histol Histopathol 16:1275–1285PubMedGoogle Scholar
  6. 6.
    Braun GS, Horster S, Wagner KS et al (2007) Cryoglobulinemic vasculitis: classification and clinical and therapeutic aspects. Postgrad Med J 83:87–94PubMedCrossRefGoogle Scholar
  7. 7.
    Sterling RK, Bralow SP (2006) Extrahepatic manifestations of hepatitis C virus. Curr Gastroenterol Rep 8:53–59PubMedCrossRefGoogle Scholar
  8. 8.
    Tavoni A, Mosca M, Feri C et al (1995) Guidelines for the management of essential mixed cryoglobulinemia. Clin Exp Rheumatol 13(Suppl):191S–195SGoogle Scholar
  9. 9.
    Saadoun D, Delluc A, Piette JC, Cacoub P (2008) Treatment of hepatitis C-associated mixed cryoglobulinemia vasculitis. Curr Opin Rheumatol 20:23–28PubMedGoogle Scholar
  10. 10.
    Kayali Z, LaBrecque DR, Schmidt WN (2006) Treatment of hepatitis C cryoglobulinemia: mission and challenges. Curr Treat Options Gastroenterol 9:497–507PubMedCrossRefGoogle Scholar
  11. 11.
    Bonomo L, Casato M, Afeltra A, Caccavo D (1987) Treatment of idiopathic mixed cryoglobulinemia with alpha interferon. Am J Med 83:726–730PubMedCrossRefGoogle Scholar
  12. 12.
    Casato M, Lagana B, Antonelli G et al (1991) Long-term results of therapy with interferon-alpha for type II essential mixed cryoglobulinemia. Blood 78:3142–3147PubMedGoogle Scholar
  13. 13.
    Misiani R, Bellavita P, Fenili D et al (1994) Interferon alfa-2a therapy in cryoglubulinemia associated with hepatitis C virus. N Engl J Med 330:751–756PubMedCrossRefGoogle Scholar
  14. 14.
    Lauta VM, DeSangro MA (1995) Long-term results regarding the use of recombinant interferon alpha-2b in the treatment of II type mixed essential cryoglobulinemia. Med Oncol 12:223–230PubMedCrossRefGoogle Scholar
  15. 15.
    Casato M, Agnello V, Pucillo LP et al (1997) Predictors of long-term response to high-dose interferon therapy in type II cryoglobulinemia associated with hepatitis C virus infection. Blood 90:3865–3873PubMedGoogle Scholar
  16. 16.
    Migliaresi S, Tirri G (1995) Interferon in the treatment of mixed cryoglobulinemia. Clin Exp Rheumatol 13(Suppl):175S–180SGoogle Scholar
  17. 17.
    Akriviadis E, Xanthakis I, Navrozidou C, Papadopoulos A (1997) Prevalence of cryoglubulinemia in chronic hepatitis C virus infection and response to treatment with interferon-alpha. J Clin Gastroenterol 25:612–618PubMedCrossRefGoogle Scholar
  18. 18.
    Pellicano R, Marietti G, Leone N et al (1999) Mixed crioglobulinemia associated with hepatitis C virus infection: a predictor factor for treatment with interferon? J Gastroenterol Hepatol 14:1108–1111PubMedCrossRefGoogle Scholar
  19. 19.
    Mazzaro C, Carniello GS, Colle R et al (1997) Interferon therapy in HCV-positive mixed cryoglobulinemia: viral and host factors contributing to efficacy of the therapy. Ital J Gastroenterol Hepatol 29:343–350PubMedGoogle Scholar
  20. 20.
    Ferri C, Marzo E, Longombardo G et al (1993) Interferon-alpha in mixed cryoglobulinemia patients: a randomized, crossover-controlled trial. Blood 81:1132–1136PubMedGoogle Scholar
  21. 21.
    Cresta P, Musset L, Cacoub P et al (1999) Response to interferon α treatment and disappearance of cryoglobulinemia in patients infected by hepatitis C virus. Gut 45:122–128PubMedCrossRefGoogle Scholar
  22. 22.
    Donada C, Crucitti A, Donadon V et al (1998) Interferon alpha and ribavirin combination therapy in patients with chronic hepatitis C and mixed cryoglobulinemia. Blood 92:2983–2984PubMedGoogle Scholar
  23. 23.
    Mazzaro C, Lacchin T, Moretti M et al (1995) Effects of two different alpha-interferon regimens on clinical and virological findings in mixed cryoglobulinemia. Clin Exp Rheumatol 13(Suppl):181S–185SGoogle Scholar
  24. 24.
    Naarendorp M, Kallemuchikkal U, Nuovo GJ, Gorevic PD (2001) Longterm efficacy of interferon-alpha for extrahepatic disease associated with hepatitis C virus infection. J Rheumatol 28:2466–2473PubMedGoogle Scholar
  25. 25.
    Durand JM, Cacoub P, Lunel-Fabiani F et al (1998) Ribavirin in hepatitis C related cryoglobulinemia. J Rheumatol 25:1115–1117PubMedGoogle Scholar
  26. 26.
    D’Amico E, Chincoli C, Cacciatore P et al (2005) Effects of combined antiviral therapy on asymptomatic mixed cryoglobulinemia in naive patients with chronic hepatitis C virus infection: a preliminary study. Dig Dis Sci 50:2344–2347PubMedCrossRefGoogle Scholar
  27. 27.
    Zuckerman E, Keren D, Slobodin G et al (2000) Treatment of refractory, symptomatic, hepatitis C virus related mixed cryoglobulinemia with ribavirin and interferon-α. J Rheumatol 27:2172–2178PubMedGoogle Scholar
  28. 28.
    Schmidt WN, LaBrecque DR, Voigt MD (2001) Combination antiviral therapy in patients with chronic hepatitis C and cryoglobulinemia. Hepatology 34:421AGoogle Scholar
  29. 29.
    Parise ER, Oliveira AC, Ferraz ML et al (2007) Cryoglobulinemia in chronic hepatitis C: clinical aspects and response to treatment with interferon alpha and ribavirin. Rev Inst Med Trop Sao Paulo 49:67–72PubMedCrossRefGoogle Scholar
  30. 30.
    Cacoub P, Lidove O, Maisonobe T et al (2002) Interferon-α and ribavirin treatment in patients with hepatitis C virus-related systemic vasculitis. Arthritis Rheum 46:3317–3326PubMedCrossRefGoogle Scholar
  31. 31.
    Calleja JL, Albillos A, Moreno-Otero R et al (1999) Sustained response to interferon-α or to interferon-α plus ribavirin in hepatitis C virus-associated symptomatic mixed cryoglobulinemia. Aliment Pharmacol Ther 13:1179–1186PubMedCrossRefGoogle Scholar
  32. 32.
    Mazzaro C, Zorat F, Caizzi M et al (2005) Treatment with peg-interferon alpha-2b and ribavirin of hepatitis C virus associated mixed cryoglobulinemia: a pilot study. J Hepatol 42:632–638PubMedCrossRefGoogle Scholar
  33. 33.
    Cacoub P, Saadoun D, Limal N et al (2005) PEGylated interferon alfa-2b and ribavirin treatment in patients with hepatitis c virus-related systemic vasculitis. Arthritis Rheum 52:911–915PubMedCrossRefGoogle Scholar
  34. 34.
    Saadoun D, Resche-Rigon M, Thibault V et al (2006) Antiviral therapy for hepatitis C virus-associated mixed cryoglobulinemia vasculitis. Arthritis Rheum 54:3696–3706PubMedCrossRefGoogle Scholar
  35. 35.
    Dammacco F, Sansonno D, Han JH et al (1994) Natural interferon-alpha versus its combination with 6-methyl-prednisolone in the therapy of type II mixed cryoglobulinemia: a long-term, randomized, controlled study. Blood 84:3336–3343PubMedGoogle Scholar
  36. 36.
    Hausfater P, Cacoub P, Assogba U et al (2002) Plasma exchange and interferon-alpha pharmacokinetics in patients with hepatitis C virus-associated systemic vasculitis. Nephron 91:627–630PubMedCrossRefGoogle Scholar
  37. 37.
    Ahmed MS, Wong CF (2007) Should rituximab be the rescue therapy for refractory mixed cryoglobulinemia associated with hepatitis C? J Nephrol 20:350–356PubMedGoogle Scholar
  38. 38.
    Zaja F, De Vita S, Mazzaro C et al (2003) Efficacy and safety of rituximab in type II mixed cryoglobulinemia. Blood 101:3827–3834PubMedCrossRefGoogle Scholar
  39. 39.
    Sansonno D, De Re V, Lauletta G et al (2003) Monoclonal antibody treatment of mixed cryoglobulinemia resistant to interferon α with an anti-CD20. Blood 101:3818–3826PubMedCrossRefGoogle Scholar
  40. 40.
    Sansonno D, Tucci FA, Montrone M et al (2007) B-cell depletion in the treatment of mixed cryoglobulinemia. Dig Liver Dis 39(Suppl):116S–121SCrossRefGoogle Scholar
  41. 41.
    Lamprecht P, Lerin-Lozano C, Merz H et al (2003) Rituximab induces remission in refractory HCV associated cryoglobulinemic vasculitis. Ann Rheum Dis 62:1230–1233PubMedCrossRefGoogle Scholar
  42. 42.
    Saadoun D, Resche-Rigon M, Sene D et al (2008) Rituximab combined with Peg-interferon-ribavirin in refractory hepatitis C virus-associated cryoglobulinemia vasculitis. Ann Rheum Dis 67:1431–1436PubMedCrossRefGoogle Scholar
  43. 43.
    Fabrizi F, Lunghi G, Messa P, Martin P (2008) Therapy of hepatitis C virus-associated glomerulonephritis: current approaches. J Nephrol 21:813–825PubMedGoogle Scholar
  44. 44.
    Levine JW, Gota C, Fessler BJ, Calabrese LH, Cooper SM et al (2005) Persistent cryoglobulinemic vasculitis following successful treatment of hepatitis C virus. J Rheumatol 32:1164–1167PubMedGoogle Scholar
  45. 45.
    Landau DA, Saadoun D, Halfon P et al (2008) Relapse of hepatitis C virus-associated mixed cryoglobulinemia vasculitis in patients with sustained viral response. Arthritis Rheum 58:604–661PubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag Italia 2012

Authors and Affiliations

  • José Luis Calleja Panero
    • 1
  • Juan de la Revilla Negro
    • 1
  • Fernando Pons Renedo
    • 2
  1. 1.Gastroenterology and Hepatology DepartmentHospital Universitario Puerta de Hierro MajadahondaMajadahonda, MadridSpain
  2. 2.Department of Gastroenterology and HepatologyHospital Universitario Puerta de Hierro MajadahondaMajadahonda, MadridSpain

Personalised recommendations